A Safety Study of Mebendazole in Children 2 to 10 Years of Age (NCT01173562) | Clinical Trial Compass
CompletedPhase 3
A Safety Study of Mebendazole in Children 2 to 10 Years of Age
Tanzania397 participantsStarted 2010-02
Plain-language summary
The purpose of this study is to assess the safety and tolerability of mebendazole 500-mg chewable tablet formulation in a pediatric population. Mebendazole is a drug used for the treatment of soil-transmitted parasitic helminth (STH) (ie, parasitic worm) infections such as pinworm, whipworm, common roundworm, common hookworm, and American hookworm.
Who can participate
Age range2 Years ā 10 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Be an otherwise healthy child based on medical history, physical examination, vital signs, and concomitant medications and live in a high-prevalence area where parasite infection is endemic (ie, Prevalent in or peculiar to a particular locality, region, or people)
* Have teeth and be able to chew the mebendazole chewable tablet
* Girls must be premenarchal
* Parent(s)/guardians of study participants (or their legally-accepted representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to have their child participate in the study
Exclusion Criteria:
* Have a history of clinically significant liver or renal insufficiency
* cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic (eg, anemia), rheumatologic, psychiatric, or metabolic disturbances that, in the opinion of the investigator, renders the candidate not suitable for mebendazole treatment
* Have a suspected massive intestinal parasitic infection, based on history and physical findings, as determined by the principal investigator
* Have any condition that, in the opinion of the investigator, would compromise the well-being of the study participant or the study or prevent the study participant from meeting or performing study requirements
What they're measuring
1
The number, severity, relationship to study drug, and type of adverse events reported.
Timeframe: Baseline (Day 1) to the end of study (Day 3) or early withdrawal visit
Trial details
NCT IDNCT01173562
SponsorJohnson & Johnson Pharmaceutical Research & Development, L.L.C.